Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Capecitabine Adjuvant Therapy for Extrahepatic Biliary Tract Cancer
NCT06717464Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in extrahepatic biliary tract cancer (ECC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Nov 2024; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
extrahepatic biliary tract cancer (ECC)
Beyond the preview
Go deeper on NCT06717464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717464.